Replies to post #211598 on Biotech Values

[DewDiligence]

(OCRX)—Synlogic starts phase-1 trial of anti-ammonia drug, SYNB1020:

https://www.businesswire.com/news/home/20170619005356/en

Synlogic has dosed the first subject in a Phase 1 healthy volunteers study designed to assess the safety and tolerability of its lead compound, SYNB1020. SYNB1020 is an investigational Synthetic Biotic medicine intended as an oral treatment for hyperammonemia in diseases such as urea cycle disorders (UCD) and hepatic encephalopathy (HE)…

SYNB1020 is the first in a novel class of living medicines under development by Synlogic. Synthetic Biotic medicines are generated using the company’s proprietary technology platform, leveraging synthetic biology to genetically reprogram probiotic bacteria to perform critical functions or deliver therapeutic factors that compensate for those missing or damaged due to disease.